Skip to main content


The Board of Moberg Derma AB (OMX: MOB) assessed that the company has the potential to show profitability already full-year 2012 based on continued positive development and revenue growth. Moberg Derma therefore updates its financial goals. Its short-term goal of operative profit and cash flow for the full-year 2013 is omitted, since it is assessed that profitability can be achieved already 2012. The long term (3-5 years) financial goal remains - to achieve an operating margin before depreciation and amortization (operating profit as a percentage of sales) of 25% with continued strong growth.

”Strong international sales growth for Nalox™/Emtrix® in combination with a significantly improved gross margin gives us opportunities to achieve profitability as early as 2012”, say Peter Wolpert, CEO and founder of Moberg Derma.

About this information
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am (CET) on March 13th, 2012.

For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35

Magnus Persson, IR
Mobile: +46 73-355 26 01

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: